Several pharmaceutical companies, including Roche, Johnson & Johnson, Sage Therapeutics, and Otsuka, have discontinued Alzheimer's and Parkinson's disease programs in 2024.
Otsuka Pharmaceutical's sibeprenlimab demonstrated a statistically significant and clinically meaningful reduction in 24-hour urine protein-to-creatinine ratio (uPCR) compared to placebo.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.